Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial

Table 1 Patient demographics

Characteristics	IVR group (n = 44)	IVC group (n = 46)	P value
Eyes/patients	44/40	46/40	–
Age (years)	54.50 ± 9.23	54.28 ± 10.61	0.920
Male/female	22/18	20/20	0.654
BMI (kg/m²)	24.31 ± 2.00	24.20 ± 1.94	0.814
Systemic profile
Type of diabetes, n (%)			0.745
T1DM, n (%)	5 (12.5)	6 (15)
T2DM, n (%)	35 (87.5)	34 (85)
HbA1c (%), mean ± SD	7.03 ± 1.93	6.94 ± 1.71	0.831
Duration of DM (years), median (IQR)	8.50 (5.00, 11.00)	8.50 (5.00, 11.75)	0.693
Hypertension, n (%)	23 (57.5)	18 (45)	0.263
Ocular profile, n (%)
History of laser	11 (25.0)	14 (30.4)	0.565
Pseudophakic	3 (6.8)	2 (4.3)	0.609
Indication for surgery, n (%)			0.821
Blurring VH	20 (45.5)	22 (47.8)
TRD	13 (29.5)	15 (32.6)
Diffuse FP	11 (25.0)	9 (19.6)
BCVA (logMAR)	1.50 ± 0.70	1.51 ± 0.52	0.939
IOP (mmHg)	15.16 ± 3.09	14.67 ± 3.37	0.479
CRT (μm)	313.89 ± 122.97	314.61 ± 108.01	0.976
Extent of VAG, n (%)
0	0 (0.0)	0 (0.0)	0.934
1	11 (25.0)	12 (26.1)
2	19 (43.2)	21 (45.7)
3	14 (31.8)	13 (28.3)

IVR = intravitreal ranibizumab; IVC = intravitreal conbercept; BMI = body mass index; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; HbA1c = hemoglobin A1c; SD = standard deviation; IQR = interquartile range; VH = vitreous hemorrhage; TRD = tractional retinal detachment; FP = fibrovascular proliferation; logMAR = logarithm of minimum angle of resolution; BCVA = best-corrected visual acuity; IOP = intraocular pressure; CRT = central retinal thickness; VAG = vitreoretinal adhesion grade

ISSN: 2326-0254